Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3151 to 3165 of 8221 results

  1. MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)

    Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.

  2. Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment) (HTG619)

    NICE no longer plans to develop guidance on Freelite assays for diagnosing multiple myeloma and related conditions in primary care.

    Sections for HTG619

  3. EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (HTG611)

    Evidence-based recommendations on EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules.

  4. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack (HTG724)

    Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.

  5. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719)

    Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer.

  6. Artificial intelligence (AI)-derived software to help clinical decision making in stroke (HTG708)

    Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke.

  7. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care (HTG690)

    Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care.

  8. FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (HTG682)

    Evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care.

  9. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (HTG735)

    Evidence-based recommendations on home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome.

  10. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices (HTG730)

    Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices.

  11. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (HTG729)

    Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD).

  12. Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (HTG467)

    Evidence-based recommendations on 2 adjunctive colposcopy technologies (the DYSIS colposcope with DYSISmap and the ZedScan I) for assessing suspected cervical abnormalities in people having colposcopy.

  13. PredictSURE IBD and IBDX to guide treatment of Crohn's disease (HTG610)

    Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease.

  14. SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea (HTG598)

    Evidence-based recommendations on SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea.

  15. QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography (HTG571)

    Evidence-based recommendations on QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography.